Literature DB >> 26718483

MicroRNA-340 inhibits prostate cancer cell proliferation and metastasis by targeting the MDM2-p53 pathway.

Kai Huang1, Yuxin Tang1, Leye He1, Yingbo Dai1.   

Abstract

An increasing number of studies have demonstrated the important role of microRNAs (miRNAs) in modulating cancer progression and metastasis, but the mechanisms by which miRNAs regulate prostate cancer (PCa) tumorigenesis remain poorly understood. In the present study, we found that miR-340 may act as a tumor suppressor based on our finding that it was significantly downregulated in PCa tumor tissues and cell lines. Moreover, the expression of miR-340 was found to be correlated with the inhibition of cell proliferation, migration and invasion in vitro, and had a suppressive effect on tumor growth in a xenograft mouse model as well. The suppressive effect of miR-340 overexpression was observed in cell lines DU145 and BPH-1 which express wild-type (WT) p53. However, in the p53-null PC-3 cell line, the suppressive effect was not found, indicating that miR-340 may play a critical role in the p53 pathway. Further investigation revealed that mouse double minute 2 (MDM2), an important regulator of p53, was targeted by miR-340 through the direct binding to the 3'UTR of MDM2, which inhibited MDM2 translation. In addition, miR-340 expression stabilized p53 protein levels which caused an increase in p21 expression but a decrease in the anti‑apoptotic protein, BCL-2, in the p53 WT cell lines. Moreover, the miR-340-mediated inhibition of cell progression was mitigated by re-expressing MDM2 in the stable miR‑340-overexpressing PCa cell line, which harbors WT p53. Our findings suggest that miR-340 may function as a novel tumor suppressor in PCa through the MDM2-p53 pathway by directly targeting MDM2, which may be a promising miRNA-targeted therapy for PCa.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26718483     DOI: 10.3892/or.2015.4458

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  23 in total

1.  [Role of miRNA-340 in modulating gastric cancer cell proliferation and bioinformatic analysis].

Authors:  Jian Wang; Wenjing Chen; Huijuan Lin; Jiangyu Zhang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-07-30

2.  Human serum miR-34a as an indicator of exposure to ionizing radiation.

Authors:  Mohammad Halimi; Ahmad Shahabi; Dariush Moslemi; Hadi Parsian; S Mohsen Asghari; Reyhaneh Sariri; Farshid Yeganeh; Ebrahim Zabihi
Journal:  Radiat Environ Biophys       Date:  2016-08-25       Impact factor: 1.925

3.  The emerging role of extracellular vesicle-derived miRNAs: implication in cancer progression and stem cell related diseases.

Authors:  Qiwei Yang; Michael P Diamond; Ayman Al-Hendy
Journal:  J Clin Epigenet       Date:  2016-01-31

Review 4.  The Role of NcRNAs to Regulate Immune Checkpoints in Cancer.

Authors:  Yicun Jiang; Leilei Zhao; Yiwen Wu; Sijun Deng; Pu Cao; Xiaoyong Lei; Xiaoyan Yang
Journal:  Front Immunol       Date:  2022-04-06       Impact factor: 8.786

Review 5.  Epigenetic and miRNAs Dysregulation in Prostate Cancer: The role of Nutraceuticals.

Authors:  Alessandra Bosutti; Fabrizio Zanconati; Gabriele Grassi; Barbara Dapas; Sabina Passamonti; Bruna Scaggiante
Journal:  Anticancer Agents Med Chem       Date:  2016       Impact factor: 2.505

6.  Regulation of FBXO4-mediated ICAM-1 protein stability in metastatic breast cancer.

Authors:  Jae-Hyeok Kang; Mi-Young Choi; Yan-Hong Cui; Neha Kaushik; Nizam Uddin; Ki-Chun Yoo; Min-Jung Kim; Su-Jae Lee
Journal:  Oncotarget       Date:  2017-09-15

7.  MicroRNA-340 inhibits invasion and metastasis by downregulating ROCK1 in breast cancer cells.

Authors:  Niraj Maskey; Dengfeng Li; Hui Xu; Hongming Song; Chenyang Wu; Kaiyao Hua; Jialu Song; Lin Fang
Journal:  Oncol Lett       Date:  2017-06-21       Impact factor: 2.967

8.  Meta-analysis of miRNA expression profiles for prostate cancer recurrence following radical prostatectomy.

Authors:  Elnaz Pashaei; Elham Pashaei; Maryam Ahmady; Mustafa Ozen; Nizamettin Aydin
Journal:  PLoS One       Date:  2017-06-26       Impact factor: 3.240

9.  MicroRNA-340-5p modulates cisplatin resistance by targeting LPAATβ in osteosarcoma.

Authors:  L Song; P Duan; Y Gan; P Li; C Zhao; J Xu; Z Zhang; Q Zhou
Journal:  Braz J Med Biol Res       Date:  2017-04-20       Impact factor: 2.590

10.  MDM2 is a potential therapeutic target and prognostic factor for ovarian clear cell carcinomas with wild type TP53.

Authors:  Chinami Makii; Katsutoshi Oda; Yuji Ikeda; Kenbun Sone; Kosei Hasegawa; Yuriko Uehara; Akira Nishijima; Kayo Asada; Takahiro Koso; Tomohiko Fukuda; Kanako Inaba; Shinya Oki; Hidenori Machino; Machiko Kojima; Tomoko Kashiyama; Mayuyo Mori-Uchino; Takahide Arimoto; Osamu Wada-Hiraike; Kei Kawana; Tetsu Yano; Keiichi Fujiwara; Hiroyuki Aburatani; Yutaka Osuga; Tomoyuki Fujii
Journal:  Oncotarget       Date:  2016-11-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.